Literature DB >> 19733023

Radiofrequency ablation of subcapsular hepatocellular carcinoma: single center experience.

P Filippousis1, E Sotiropoulou, A Manataki, O Konstantinopoulos, L Thanos.   

Abstract

PURPOSE: To present a single center results, regarding radiofrequency ablation (RFA) of subcapsular hepatocellular carcinoma (HCC).
MATERIALS AND METHODS: Forty patients with subcapsular HCC were treated with RFA under CT guidance for fifty-two discrete lesions in our institution. Twenty-eight patients underwent ablation of a solitary tumor and twelve patients underwent RFA of two tumors. Six patients had a subcapsular HCC with an exofitic location. All lesions had a diameter of <4 cm. We used two types of generators and electrodes: spiral electrode and expandable electrode. Needle track ablation was performed in all cases. Follow-up consisted of an abdomen computed tomography (CT) scan after contrast administration immediately after each session and then after one, three, six, and twelve months.
RESULTS: In forty-eight lesions complete tumor ablation was depicted at the one month CT scan. In four lesions with residual viable tumor, a second session was performed. After the second ablation no residual tumor was observed in any patient. No major complications occurred in any of our patients. Fever with a temperature up to 39 °C was documented during the first days as part of the post-ablation syndrome in thirteen patients (32.2%). Seeding along the needle track was observed in none of our patients. Local tumor progression, was observed in ten lesions (19.25%) and in all cases a second RFA session was performed with optimal results.
CONCLUSION: Subcapsular location should not be considered as a contraindication for liver RFA.
Copyright © 2009. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Year:  2009        PMID: 19733023     DOI: 10.1016/j.ejrad.2009.07.003

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  6 in total

1.  Percutaneous thermal ablation of subcapsular hepatocellular carcinomas: influence of tumor-surface contact and protrusion on therapeutic efficacy and safety.

Authors:  Akeanong Worakitsitisatorn; David S Lu; Min Woo Lee; Nazanin H Asvadi; Amin Moshksar; Alexander D Yuen; Justin McWilliams; Steven S Raman
Journal:  Eur Radiol       Date:  2019-12-10       Impact factor: 5.315

2.  Laparoscopic radiofrequency ablation versus percutaneous radiofrequency ablation for subphrenic hepatocellular carcinoma.

Authors:  Min Hwan Kwak; Min Woo Lee; Seong Eun Ko; Hyunchul Rhim; Tae Wook Kang; Kyoung Doo Song; Jong Man Kim; Gyu-Seong Choi
Journal:  Ultrasonography       Date:  2022-02-09

3.  Predictive Value of Procalcitonin for Bacterial Infection after Transarterial Chemoembolization or Radiofrequency Ablation for Hepatocellular Carcinoma.

Authors:  Seung Ji Kang; Uh Jin Kim; Seong Eun Kim; Joon Hwan An; Mi Ok Jang; Dae-Seong Myung; Kyung-Hwa Park; Sook-In Jung; Sung Bum Cho; Hee-Chang Jang; Young Eun Joo
Journal:  Dis Markers       Date:  2018-04-17       Impact factor: 3.434

4.  Transarterial chemoembolization plus multi-imaging-guided radiofrequency ablation for elimination of hepatocellular carcinoma nodules measuring 3.1 to 5.0 cm: a single-center study.

Authors:  Wang Haochen; Wang Jian; Song Li; Lv Tianshi; Tong Xiaoqiang; Zou Yinghua
Journal:  J Int Med Res       Date:  2018-04-23       Impact factor: 1.671

5.  Comparison of Percutaneous Radiofrequency Ablation for Subcapsular and Non-Subcapsular Colorectal Cancer Liver Metastases.

Authors:  Hongjie Fan; Xiaoyan Wang; Jiali Qu; Wei Lu; Shufeng Xu; Xia Wu; Jingya Xia; Yanhua Zhang; Jihong Sun; Xiaoming Yang
Journal:  Front Oncol       Date:  2021-05-14       Impact factor: 6.244

6.  Radiofrequency ablation versus repeat hepatectomy in the treatment of recurrent hepatocellular carcinoma in subcapsular location: a retrospective cohort study.

Authors:  Fuqun Wei; Qizhen Huang; Yang Zhou; Liuping Luo; Yongyi Zeng
Journal:  World J Surg Oncol       Date:  2021-06-14       Impact factor: 2.754

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.